QIAGEN expands presence in Thailand to serve life sciences

Food and Healthcare Press Releases Friday June 16, 2017 10:46
Bangkok--16 Jun--ABM
Opens Bangkok office and launches collaborations for malaria and cancer research

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion in Thailand and opened an office in Bangkok to enhance relationships with life science researchers and healthcare providers in the growing market. QIAGEN also announced two new collaborations in Thailand: a molecular techniques center established with the faculty for tropical medicine at Mahidol University and a collaboration with Ramathibodi Hospital to study genomic insights from next-generation sequencing (NGS).

"We are pleased to expand our commitment to the people of Thailand, where we have built relationships with medical institutions and the government for more than 16 years. As we open our new Bangkok office, we are also introducing new collaborations with two of the country's leading medical institutions," said Mr. William Lin, Director of Commercial Operations for QIAGEN Thailand. "We look forward to providing Thai scientists and healthcare providers with innovative Sample to Insight solutions for molecular testing, including our NGS solutions, as we seek to make improvements in life possible."

The collaboration with Mahidol University has established the QIAGEN–TropMed Center for Molecular Techniques in conjunction with the Faculty of Tropical Medicine to support research using molecular biology techniques.

"We are happy to join with QIAGEN in creating the TropMed Center for Molecular Techniques to bring the benefits of genomic insights to research on malaria and other diseases. Our partnership will demonstrate the potential of academic-industry collaboration, as well as educate the younger generation in techniques of molecular biology," said Dr. Wang Nguitragool, Assistant Professor, Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine of Mahidol University.

QIAGEN has joined with the Medical Genomic Center at Ramathibodi Hospital in Bangkok to help guide personalized healthcare treatment decisions using QIAGEN NGS solutions.

"QIAGEN NGS solutions, highly sensitive sequencing analyzes liquid biopsies or tissue samples to identify genetic mutations and enable doctors to select the best possible treatment. We expect this collaboration to have significant benefits for cancer patients," said Dr. Thanyanan Reungwetwattana, Assistant Professor, Division of Medical Oncology, Department of Medicine, Faculty of Medicine of Ramathibodi Hospital.

The expansion in Thailand supports QIAGEN's strategy of investing in emerging markets, where the use of advanced molecular technologies for medical care and research is growing rapidly. "The German-Thai Chamber of Commerce is proud to see another established German brand set root in Thailand. I am very happy to see that QIAGEN is expanding to Thailand because they bring their expertise to the local science community and contribute to the improvement of the life of the Thai people," said Dr. Roland Wein, Executive Director, German-Thai Chamber of Commerce. In 2016, QIAGEN sales in its top seven emerging markets grew 19% and contributed 16% of total net sales of $1.34 billion.


Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics